We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 12

You look marvelous: just ask FDA whether beauty is in the eye of the beholder
  • Arnall Golden Gregory LLP
  • USA
  • April 21 2015

Many of us remember Billy Crystal's "You Look Marvelous" one-liner from "Saturday Night Live," where the comedic routine frequently ended with "It's


A human research study involving a medical food or cosmetic may require an IND
  • Arnall Golden Gregory LLP
  • USA
  • November 14 2013

The Food and Drug Administration's (FDA's) Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) and


FDA warns L’Oreal about anti-aging claims for skin care products
  • Arnall Golden Gregory LLP
  • USA
  • September 26 2012

On September 7, 2012, the Food and Drug Administration sent a Warning Letter to Lancôme, a division of L’Oreal, concerning claims made on the company’s website for its skin care products


FDA publishes draft guidance on nanomaterials in cosmetic products
  • Arnall Golden Gregory LLP
  • USA
  • May 9 2012

Cosmetic products and ingredients (except colors) are not subject to premarket clearance by the Food and Drug Administration (FDA) and the manufacturer is responsible for the safety of any cosmetic product it distributes


FDA Food Center director Landa testifies before Congress for greater cosmetic regulation
  • Arnall Golden Gregory LLP
  • USA
  • April 5 2012

On March 27, 2012, Director of the Food and Drug Administration (FDA) Center for Food Safety and Applied Nutrition Michael M. Landa testified on the “Current State of Cosmetics” before the U.S. House Subcommittee on Health of the Energy and Commerce Committee


Congress sits on proposed new rules for FDA-regulated industries pending election outcomes
  • Arnall Golden Gregory LLP
  • USA
  • March 14 2012

More than 70 bills to amend the way that foods, drugs, cosmetics and medical devices are governed in the U.S. have been introduced in the past year


FDA draft guidance broadens “new dietary ingredient” definition and extends notification requirements
  • Arnall Golden Gregory LLP
  • USA
  • September 13 2011

The Food and Drug Administration (FDA) has recently published a draft guidance on New Dietary Ingredient Notifications and Related Issues (announced in the July 17, 2011, Federal Register


Grandfathered drugs: what’s behind the huge price increases?
  • Arnall Golden Gregory LLP
  • USA
  • June 1 2011

Drug prices are supposed to go down over time, as generic versions of innovative drugs are introduced to the market and drive prices down


FDA requests input on user fee program for biosimilar and interchangeable biological products
  • Arnall Golden Gregory LLP
  • USA
  • May 25 2011

The U.S. Food and Drug Administration (FDA) announced this month that it is seeking industry and stakeholder input on the development of a user fee program for biosimilar and interchangeable biological products


FDA launches website to track status of 515 Program Initiative
  • Arnall Golden Gregory LLP
  • USA
  • February 21 2011

The Food and Drug Administration (FDA) recently launched a new webpage that provides status updates on the agency's 515 Program Initiative